News | PET-CT | June 12, 2017

Philips Highlights the Value of Advanced Molecular Imaging at SNMMI 2017

Showcases continued commitment to creating innovative solutions that enhance and simplify the clinical decision making path, from diagnosis to treatment, to drive more personalized care

PET/CT

Philips announced that it will be showcasing molecular imaging solutions highlighting Philips’ commitment to innovation and more personalized care at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2017 Annual Meeting. Molecular imaging provides insight into molecular and cellular processes in the body, and has the potential to transform healthcare by offering earlier detection and more precise treatment of diseases. Philips continues to bring solutions into the field of nuclear medicine that enhance quantitative accuracy and enable new clinical applications driving more personalized care and workflow efficiencies from diagnosis to treatment.

Nuclear medicine technology has significantly evolved over the years – growing from just scanners to solutions that comprise systems and advanced informatics, for enhanced image quality, quantification and analytics. As value-based care changes the way healthcare organizations approach care delivery, there is a greater need for easy to use, fast and precise imaging. With increased access to better data, clinicians are looking for ways to make that data actionable, especially in terms of customizing patient treatment. Molecular imaging accomplishes that, allowing physicians to make decisions based on the specific molecular and cellular patterns of disease in addition to the patient’s anatomy. 

“Molecular imaging today allows physicians to make decisions with greater insight, precision and confidence, bringing healthcare one step closer to personalized care,” said Kirill Shalyaev, Ph.D., Business Leader, Advanced Molecular Imaging, Philips. “Philips has made a lasting impact in nuclear medicine by providing clinicians with innovations such as Time-of-Flight PET and digital PET/CT, and we remain dedicated to developing solutions that simplify the path to clinical decision making for more confident diagnosis and a faster path to treatment.”

Even with its significant growth in past years, the opportunity for further innovation and growth in nuclear medicine remains, continuing to maximize its value and impact. The latest solutions from Philips include:

Vereos Digital PET/CT – A fully digital PET/CT system featuring Philips proprietary Digital Photon Counting (DPC) technology. Vereos offers improved detectability and characterization of small lesions. The system provides uncompromised detectability and quantification at half the PET dose. Vereos also provides lesion detectability in one tenth of the time. 

Ingenuity TF PET/CT – Leverages Philips’ Astonish TF technology for enhanced image contrast, resolution, and quality. Features Philips’ proprietary xPand5 quantification tools to assist in measuring and monitoring disease progression. These technologies join CT advances, such as iPatient, iDose⁴ and metal artifact reduction for implants (O-MAR), to drive confidence and consistency through personalized patient centric workflow.

IntelliSpace Portal 9.0 – IntelliSpace Portal 9.0 – The latest edition of Philips’ comprehensive, advanced visualization and analysis platform offers quantitative tumor tracking and treatment response tools with a streamlined workflow for follow‐up and analysis in oncology cases. IntelliSpace Portal 9.0 provides enterprise‐wide access to a comprehensive suite of Molecular Imaging processing and review applications for general Nuclear Medicine, SPECT, SPECT/CT and PET/CT.

SPECT Solutions – To fulfill the need for clinically dependable SPECT systems, Philips provides cost-efficient cardiac and general-purpose SPECT solutions that maximize the return on investment.

For more information: www.philips.com 

Related Content

Sectra Surveys Radiologists on Value of Machine Learning
News | Artificial Intelligence | October 16, 2017
October 16, 2017 — A new report from medical imaging...
NIH Clinical Center Releases 100,000-Plus Chest X-ray Datasets to Scientific Community
News | Artificial Intelligence | October 10, 2017
The National Institutes of Health (NIH) Clinical Center recently released over 100,000 anonymized chest X-ray images...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Strategic Radiology to Contribute to IBM Watson's Education
News | Artificial Intelligence | October 02, 2017
Thirty radiologists from seven of Strategic Radiology’s 26 member practices will contribute to work undertaken by the...
SIIM Announces Keynote Speakers for Conference on Machine Intelligence in Medical Imaging
News | Artificial Intelligence | September 21, 2017
The Society for Imaging Informatics in Medicine (SIIM) recently announced several corporate and government experts as...
Carestream Demonstrates Artificial Intelligence Tools for Clinical Collaboration Platform
News | Enterprise Imaging | September 20, 2017
Carestream Health is demonstrating advanced imaging analytics software tools designed to enhance value in the delivery...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Matrix Analytics Beginning Validation of Deep Learning Lung CT Tools
News | Lung Cancer | September 13, 2017
Matrix Analytics announced it will clinically validate its LungDirect deep learning and predictive analytics tools for...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
Overlay Init